First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
01/06/2022 - 07:00 AM
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022
Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on 150 Trial Participants
BOCA RATON, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has completed enrollment for Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal (GI) infections. FW-COV is a proprietary, oral, tablet formulation of micronized niclosamide being developed to remove SARS-CoV-2 (SARS2), the virus that causes COVID-19, from the GI tract.
RESERVOIR is designed as a two-part, two-arm, randomized, placebo-controlled Phase 2 study with a primary purpose to confirm the safety of FW-COV and assess the drug’s ability to remove the SARS-CoV-2 (SARS2) virus from the digestive tract. The 150 patients successfully enrolled in Part 2 of the trial were randomized to receive either FW-COV or a placebo treatment for 14 days and will be observed for six weeks following the end of treatment. No FW-COV drug-related serious adverse events (SAEs) have been reported from the trial participants. First Wave BioPharma expects to report top-line data in the first half of 2022.
“We are very pleased to complete enrollment of the second part of the RESERVOIR trial and look forward to reporting top-line data in the coming months,” stated James Sapirstein, President and CEO of First Wave BioPharma. “This is an important milestone for First Wave and the development of FW-COV. Based on the positive safety data observed thus far, combined with earlier published in vitro COVID efficacy data1 for niclosamide, we believe that FW-COV has the potential to contribute to the global need for new therapies against SARS2. Furthermore, because niclosamide targets the entire virus, and not just the spike protein, we believe that FW-COV may prove effective against multiple strains of COVID-19, including the Delta and Omicron variants. If RESERVOIR is successful and supported by additional data, we anticipate being in a position to submit an Emergency Use Authorization (EUA) application later this year.”
James Pennington, M.D., Chief Medical Officer of First Wave BioPharma, commented, “Safety data thus far indicates that our micronized oral niclosamide therapy is well tolerated, and we believe that further data will demonstrate that FW-COV can add a much-needed new oral anti-viral therapy to the COVID-19 treatment regimen. Millions of patients around the world already suffer complications from COVID-19, and millions more could face similar medical issues as the Omicron variant continues to fuel a surge in new infections.”
Additional information about the RESERVOIR trial can be found at www.covidgi.com and on ClinicalTrials.gov .
About COVID-19 Gastrointestinal Infections Gastrointestinal infection symptoms (severe diarrhea, vomiting and abdominal pain) have been reported in approximately 18% of COVID-19 cases.2 Of the 57 million individuals who are reported to have contracted COVID-19 in the U.S.,3 this would translate into approximately 10 million patients having GI infection. Of the 295 million cases reported globally,3 it would translate into almost 53 million patients. Furthermore, approximately 10% of patients who were infected with COVID have persistent symptoms months after their initial diagnosis.4 Approximately 86% of these COVID “long haulers” are reported to have GI infection symptoms, with 60% continuing to have diarrhea months after their initial infection.5 There is some evidence to support the view that the GI tract is a possible reservoir6 for persistence and fecal spread of the COVID-19 virus as ACE-2, the entry receptor for COVID-19, is highly expressed on GI cells. There currently is no targeted treatment for COVID GI infections.
About Niclosamide Niclosamide is a prescription small molecule drug listed as an essential medicine by the World Health Organization (WHO). Niclosamide has been safely used on millions of patients for other clinical indications. In the U.S., niclosamide was approved by the U.S. Food and Drug Administration (FDA) in 1982 for the treatment of intestinal tapeworm infections. In addition to its antihelminthic activity, niclosamide has demonstrated anti-inflammatory and anti-viral properties. There remains an urgent need to develop new medicines that can be manufactured at large scale quickly to treat COVID-19. Niclosamide was recently identified by the Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-19, with potency 40X greater than remdesivir.1 Additionally, emerging evidence confirms the severe GI-related complications of COVID and potential fecal spread of the virus.6 The Company’s clinical trials may establish that patients treated with an oral and non-systemic niclosamide formulation that delivers high local GI concentrations have decreased viral load and GI-associated symptoms of COVID. Importantly, the manufacturing process for niclosamide can be scaled up to supply large populations quickly.
FW-COV
About First Wave BioPharma, Inc. www.firstwavebio.com .
Forward-Looking Statement This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition and its announcement on the Company’s business, operating results and financial prospects; the integration of the First Wave Bio, Inc. business with the Company’s own business; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
For more information: info@azurrx.com
Media contact: Tiberend Strategic Advisors, Inc. jbennett@tiberend.com / dschemelia@tiberend.com
References: 1 Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 64:e00819-20. https://doi.org/10.1128/AAC.00819-20 .2 Gut Journal: Vol 69, Issue 6: 2020; JAMA Network: Vol 3, Issue 6: 2020; Lancet Gastroenterol Hepatol: Vol 5, Issue 5: 2020; Cheung Gastroenterology: Vol. 159, Issue 1: 2020 3 New York Times. (1/5/22) https://www.nytimes.com/interactive/2021/world/covid-cases.html 4 Rubin, R. “As their numbers grow, COVID-19 “Long Haulers” Stump Experts”. https://jamanetwork.com/journals/jama/fullarticle/2771111 September 23, 2020.5 Davis, et al. “Characterizing Long Covid in an International Cohort: 7 Months of Symptoms and their Impact”. https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v2.full.pdf 6 Troisi, J et al. COVID-19 and the gastrointestinal tract: Source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection? World J Gastroenterology. Vol. 27 (14): 2021 Apr. 14.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047540/
